Redefining Druggability.

A radically new approach for oncology and diseases with highly unaddressed medical needs

About us

PROSION Therapeutics is a biotech company with a proprietary technology combining the advantages of small molecules and biologics to unlock undruggable disease drivers.

Starting off in oncology and adjacent pathologies, we utilize our cutting-edge technology for a variety of other therapeutic areas with the mission to impact the lives of patients for the better.

Learn more About Us

Science

Meet ProMs

ProMs are the first and currently only mimetics of the Polyproline-II-Helix, a specific helix structure that is recognized by a highly abundant, yet so far undruggable class of protein targets.

ProM-based Small Molecules

As building blocks, our ProMs can be assembled into highly selective small molecule inhibitors able to unlock a previously unaddressable space within the proteome.

Unlocking Undruggables

As this newly unlocked space contains key orchestrator proteins of urgent diseases, our ProM-Platform represents a new therapeutic modality to fight highly unaddressed medical needs.

Learn more about the Science